Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-01
2008-01-01
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S011400
Reexamination Certificate
active
11321534
ABSTRACT:
The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
REFERENCES:
patent: WO 97 12905 (1997-05-01), None
patent: WO 98 21230 (1998-04-01), None
patent: WO 98 46632 (1998-10-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Sato S, et al, “High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread,” FEBS Lett. Sep. 25, 2002;528(1-3):212-6, Applicant's IDS.
Magdolen, V. et al., “Systematic Mutational Analysis of the Receptor-Binding Region of the Human Urokinase-Type Plasminogen Activator”, European Journal of Biochemistry, DE, Berlin, Vo. 237, 1996, pp. 743-751.
Sato et al., “High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread”, FEBS Letters 528 (2002), 212-216.
Buergle Markus
Kessler Horst
Potthoff Nils
Schmiedeberg Niko
Wilhelm Olaf
Gupta Anish
Heard Thomas S.
Rothwell Figg Ernst & Manbeck p.c.
Wilex AG
LandOfFree
Cyclic peptidomimetic urokinase receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic peptidomimetic urokinase receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptidomimetic urokinase receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3931470